Atopic Dermatitis: Updated Insights Into Pathophysiology and Emerging Therapies

View Full Paper

Ask AI

Bookmark

Advancements in therapies have shown significant efficacy in reducing atopic dermatitis severity, enhancing patient quality of life.
Topical phosphodiesterase‐4 inhibitors and JAK inhibitors are among the innovative treatments for atopic dermatitis.
The review emphasizes the gut-skin axis in atopic dermatitis, presenting a novel perspective on its pathogenesis.
Emerging therapies targeting cytokines like IL-13 and IL-31 offer promise for personalized treatment strategies.

Discussion

No takes yet. Share an insight, caveat, or question.

This review highlights novel therapies targeting IL-13 and IL-31 in atopic dermatitis, suggesting the importance of pathophysiological mechanisms.

Xie et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

This review highlights novel therapies targeting IL-13 and IL-31 in atopic dermatitis, suggesting the importance of pathophysiological mechanisms.